Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 9, Issue 7, 2009, Pages 409-417

  Gupta, Ravindra K ^a   Hill, Andrew ^b   Sawyer, Anthony W ^c   Cozzi Lepri, Alessandro ^a   von Wyl, Viktor ^d   Yerly, Sabine ^e   Lima, Viviane Dias ^f   Günthard, Huldrych F ^d   Gilks, Charles ^g   Pillay, Deenan ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c MetaVirology Ltd   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; BIOLOGICAL MONITORING; CLINICAL TRIAL; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; META ANALYSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67449097569     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70136-7     Document Type: Review

References (43)

1. Gilks C.F., Crowley S., Ekpini R., et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (2006) 505-510
2. Gazzard B., Bernard A.J., Boffito M., et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 7 (2006) 487-503
3. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
4. Mermin J., Were W., Ekwaru J.P., et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 371 (2008) 752-759
5. Jahn A., Floyd S., Crampin A.C., et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371 (2008) 1603-1611
6. Hogg R.S., Bangsberg D.R., Lima V.D., et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3 (2006) e356
7. Petersen M.L., van der Laan M.J., Napravnik S., Eron J.J., Moore R.D., and Deeks S.G. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 22 (2008) 2097-2106
8. Siegfried N.L., Van Deventer P.J., Mahomed F.A., and Rutherford G.W. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev 2 (2006) CD004535.
9. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
10. US Food and Drug Administration. Drugs used in the treatment of HIV infection. http://www.fda.gov/oashi/aids/virals.html (accessed May 19, 2009).
11. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK collaborative HIV cohort (UK CHIC) study. HIV Medicine 5 (2004) 115-124
12. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353 (1999) 863-868
13. Harrigan P.R., Hogg R.S., Dong W.W., et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191 (2005) 339-347
14. Ferradini L., Jeannin A., Pinoges L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367 (2006) 1335-1342
15. DART trial team. Twenty-four-week safety and tolerability of nevirapine vs abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 13 (2008) 6-16
16. Ndembi N, Pillay D, Goodall R, et al. Differences in the dynamics of viral rebound and evolution of resistance between CBV/NVP and CBV/ABC uncovered in the absence of viral load monitoring in real time: NORA substudy of the DART trial. 15th conference on retroviruses and opportunistic infections; Boston, USA; Feb 3-6, 2008. Abstract 889.
17. Kamya M.R., Mayanja-Kizza H., Kambugu A., et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 46 (2007) 187-193
18. Charles M., Noel F., Leger P., et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 86 (2008) 970-977
19. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., and Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 44 (2007) 447-452
20. Marconi V.C., Sunpath H., Lu Z., et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46 (2008) 1589-1597
21. Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364 (2004) 29-34
22. Phillips A.N., Dunn D., Sabin C., et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19 (2005) 487-494
23. von Wyl V., Yerly S., Böni J., et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167 (2007) 1782-1790
24. Tam L.W., Hogg R.S., Yip B., Montaner J.S., Harrigan P.R., and Brumme C.J. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting. HIV Med 8 (2007) 267-270
25. Mocroft A., Kirk O., Aldins P., et al. Loss to follow-up in an international, multicentre observational study. HIV Med 9 (2008) 261-269
26. Armitage P., and Berry G. Statistical methods in medical research. 3rd edn. (1994), Blackwell Scientific Publications, Oxford
27. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (2004) 1253-1263
28. Hall D, van Leth F, Schere J, et al. Genotypic analysis of reverse transcriptase in treatment-naïve HIV-1 patients treated with lamivudine, stavudine and nevirapine and/or efavirenz. 11th conference on retroviruses and opportunistic infections; San Francisco, USA; Feb 8-11, 2004. Abstract 694.
29. Podzamczer D., Ferrer E., Consiglio E., et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 7 (2002) 81-90
30. Ferrer E., Podzamczer D., Arnedo M., et al. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis 187 (2003) 687-690
31. Gallant J.E., DeJesus E., Arribas J.R., et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
32. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
33. DeJesus E., Herrera G., Teofilo E., et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39 (2004) 1038-1046
34. DeJesus E., McCarty D., Farthing C.F., et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 39 (2004) 411-418
35. Vavro C, McCarty D, Shortino D, Hetherington S. Genotypic analysis of HIV-1 from subjects experiencing virologic breakthrough while taking 3TC QD vs 3TC BID, EFV and ZDV. 42nd interscience conference on antimicrobial agents and chemotherapy; San Diego, California; Sept 27-30, 2002. Abstract H-2052.
36. Cameron W, da Silva B, Arribas J, et al. A two-year randomized controlled clinical trial in antiretroviral-naïve subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613). 16th international AIDS conference; Toronto, Canada; Aug 13-18, 2006. Abstract THLB0201.
37. Gupta R.K., Hill A., Sawyer A.W., and Pillay D. Emergence of drug resistance in HIV-1 infected patients after first-line highly active antiretroviral therapy (HAART): a systematic review of clinical trials. Clin Infect Dis 47 (2008) 712-722
38. Cozzi-Lepri A., Ruiz L., Loveday C., et al. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10 (2005) 791-802
39. Hoffmann C, Charalambous S, Ledwaba J, et al. The rate of developing ART resistance during HIV viraemia on HAART in South Africa. 16th conference on retroviruses and opportunistic infections; Montreal, Canada; Feb 8-11, 2009. Abstract 656.
40. Phillips A.N., Pillay D., Miners A.H., et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371 (2008) 1443-1451
41. Barth R.E., Wensing A.M., Tempelman H.A., Moraba R., Schuurman R., and Hoepelman A.I. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS 22 (2008) 2210-2212
42. Apisarnthanarak A., Jirayasethpong T., Sa-nguansilp C., et al. Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand. HIV Med 9 (2008) 322-325
43. Fiscus S.A., Cheng B., Crowe S.M., et al. HIV-1 viral load assays for resource-limited settings. PLoS Med 3 (2006) e417